Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
- PMID: 34126044
- DOI: 10.1016/S1470-2045(21)00196-0
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial
Abstract
Background: Conventional external beam radiotherapy is the standard palliative treatment for spinal metastases; however, complete response rates for pain are as low as 10-20%. Stereotactic body radiotherapy delivers high-dose, ablative radiotherapy. We aimed to compare complete response rates for pain after stereotactic body radiotherapy or conventional external beam radiotherapy in patients with painful spinal metastasis.
Methods: This open-label, multicentre, randomised, controlled, phase 2/3 trial was done at 13 hospitals in Canada and five hospitals in Australia. Patients were eligible if they were aged 18 years and older, and had painful (defined as ≥2 points with the Brief Pain Inventory) MRI-confirmed spinal metastasis, no more than three consecutive vertebral segments to be included in the treatment volume, an Eastern Cooperative Oncology Group performance status of 0-2, a Spinal Instability Neoplasia Score of less than 12, and no neurologically symptomatic spinal cord or cauda equina compression. Patients were randomly assigned (1:1) with a web-based, computer-generated allocation sequence to receive either stereotactic body radiotherapy at a dose of 24 Gy in two daily fractions or conventional external beam radiotherapy at a dose of 20 Gy in five daily fractions using standard techniques. Treatment assignment was done centrally by use of a minimisation method to achieve balance for the stratification factors of radiosensitivity, the presence or absence of mass-type tumour (extraosseous or epidural disease extension, or both) on imaging, and centre. The primary endpoint was the proportion of patients with a complete response for pain at 3 months after radiotherapy. The primary endpoint was analysed in the intention-to-treat population and all safety and quality assurance analyses were done in the as-treated population (ie, all patients who received at least one fraction of radiotherapy). The trial is registered with ClinicalTrials.gov, NCT02512965.
Findings: Between Jan 4, 2016, and Sept 27, 2019, 229 patients were enrolled and randomly assigned to receive conventional external beam radiotherapy (n=115) or stereotactic body radiotherapy (n=114). All 229 patients were included in the intention-to-treat analysis. The median follow-up was 6·7 months (IQR 6·3-6·9). At 3 months, 40 (35%) of 114 patients in the stereotactic body radiotherapy group, and 16 (14%) of 115 patients in the conventional external beam radiotherapy group had a complete response for pain (risk ratio 1·33, 95% CI 1·14-1·55; p=0·0002). This significant difference was maintained in multivariable-adjusted analyses (odds ratio 3·47, 95% CI 1·77-6·80; p=0·0003). The most common grade 3-4 adverse event was grade 3 pain (five [4%] of 115 patients in the conventional external beam radiotherapy group vs five (5%) of 110 patients in the stereotactic body radiotherapy group). No treatment-related deaths were observed.
Interpretation: Stereotactic body radiotherapy at a dose of 24 Gy in two daily fractions was superior to conventional external beam radiotherapy at a dose of 20 Gy in five daily fractions in improving the complete response rate for pain. These results suggest that use of conformal, image-guided, stereotactically dose-escalated radiotherapy is appropriate in the palliative setting for symptom control for selected patients with painful spinal metastases, and an increased awareness of the need for specialised and multidisciplinary involvement in the delivery of end-of-life care is needed.
Funding: Canadian Cancer Society and the Australian National Health and Medical Research Council.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests AS reports consulting services' fees, honorarium, or both for past educational seminars for Varian Medical Systems, Elekta, AstraZeneca, Medtronic Kyphon, and BrainLAB; and research grants from Elekta and Varian Medical Systems. SDM reports grants from Novartis Advanced Accelerator Applications and honorarium from Ipsen. SS reports research grants from Varian Medical Systems, Merck Sharp & Dohme, and Bayer Pharmaceuticals; and honorarium for past educational seminars and advisory board participation from AstraZeneca and Reflexion. MF reports grants from Elekta; and honorarium for past educational seminars from Elekta and Varian Medical Systems. JG, IT, MK, MGF, ML, PJM, YL, MB, JB, KD, GLM, RKW, SKL, WRP, EC, MH, and ZG declare no competing interests.
Comment in
-
Spinal stereotactic radiotherapy for painful spinal metastasis.Lancet Oncol. 2021 Jul;22(7):901-903. doi: 10.1016/S1470-2045(21)00268-0. Epub 2021 Jun 11. Lancet Oncol. 2021. PMID: 34126045 No abstract available.
-
Stereotactic body radiotherapy for painful spinal metastases.Lancet Oncol. 2021 Sep;22(9):e384. doi: 10.1016/S1470-2045(21)00421-6. Lancet Oncol. 2021. PMID: 34478668 No abstract available.
-
Stereotactic body radiotherapy for painful spinal metastases - Authors' reply.Lancet Oncol. 2021 Sep;22(9):e385. doi: 10.1016/S1470-2045(21)00459-9. Lancet Oncol. 2021. PMID: 34478669 No abstract available.
Similar articles
-
Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.Lancet Oncol. 2014 Feb;15(2):164-71. doi: 10.1016/S1470-2045(13)70556-4. Epub 2013 Dec 23. Lancet Oncol. 2014. PMID: 24369114 Clinical Trial.
-
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12. Lancet Oncol. 2019. PMID: 30770291 Clinical Trial.
-
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
-
Reirradiation spine stereotactic body radiation therapy for spinal metastases: systematic review.J Neurosurg Spine. 2017 Oct;27(4):428-435. doi: 10.3171/2017.2.SPINE16976. Epub 2017 Jul 14. J Neurosurg Spine. 2017. PMID: 28708043 Review.
-
Stereotactic body radiotherapy for spine metastases: a review of 24 Gy in 2 daily fractions.J Neurooncol. 2023 May;163(1):15-27. doi: 10.1007/s11060-023-04327-1. Epub 2023 May 8. J Neurooncol. 2023. PMID: 37155133 Review.
Cited by
-
Implementation Strategies to Promote Short-Course Radiation for Bone Metastases.JAMA Netw Open. 2024 May 1;7(5):e2411717. doi: 10.1001/jamanetworkopen.2024.11717. JAMA Netw Open. 2024. PMID: 38787561 Free PMC article. Clinical Trial.
-
A Systematic Review of Prognostic Factors in Patients with Cancer Receiving Palliative Radiotherapy: Evidence-Based Recommendations.Cancers (Basel). 2024 Apr 25;16(9):1654. doi: 10.3390/cancers16091654. Cancers (Basel). 2024. PMID: 38730606 Free PMC article. Review.
-
A new era in the management of spinal metastasis.Front Oncol. 2024 Apr 16;14:1374915. doi: 10.3389/fonc.2024.1374915. eCollection 2024. Front Oncol. 2024. PMID: 38694784 Free PMC article. Review.
-
Radiomics model based on MRI to differentiate spinal multiple myeloma from metastases: A two-center study.J Bone Oncol. 2024 Mar 28;45:100599. doi: 10.1016/j.jbo.2024.100599. eCollection 2024 Apr. J Bone Oncol. 2024. PMID: 38601920 Free PMC article.
-
Role of Metastasis-Directed Therapy in Genitourinary Cancers.Curr Treat Options Oncol. 2024 May;25(5):605-616. doi: 10.1007/s11864-024-01199-z. Epub 2024 Apr 4. Curr Treat Options Oncol. 2024. PMID: 38573430 Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical